Receive our newsletter – data, insights and analysis delivered to you
June 30, 2009

FDA Finally Approves AMAG’s Anaemia Treatment

AMAG Pharmaceutical has finally received marketing approval for its anaemia treatment Feraheme after repeated delays since the new drug application was submitted in December 2007. The US Food and Drug Administration (FDA) had twice requested more information following the application for

By cms admin

AMAG Pharmaceutical has finally received marketing approval for its anaemia treatment Feraheme after repeated delays since the new drug application was submitted in December 2007.

The US Food and Drug Administration (FDA) had twice requested more information following the application for Feraheme, an injection intended to treat iron deficiency anaemia in adults with chronic kidney disease.

AMAG spokesperson said that the approval was based on safety results from four Phase III studies of patients with chronic kidney disease and iron deficiency anaemia.

“Feraheme significantly increased haemoglobin levels as compared to oral iron across the spectrum of chronic kidney disease,” the spokesperson said.

Three studies showed a statistically significant change in haemoglobin from baseline at day 35 after the first dose.

The product is expected to reach shelves in late July 2009.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU